Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$102.74-2.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RYTM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 5.3% |
| Our one-year growth estimate | diamond | 89.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 84.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
RYTM — director transition
Dated 2026-04-03
Director — Edward T. Mathers: Mr. Mathers resigned from the Board without any disagreement.
Why it matters: The earnings report will show if Rhythm can improve its financial situation. Investors will look for signs of recovery.
Watch forThe earnings report shows revenue growth. It also shows smaller losses than before.
Also watch forThe earnings report shows ongoing losses. It also shows a drop in revenue.
Why it matters: Keeping costs low is key to reducing losses and improving finances.
Supportive ifOperating costs are below $385 million for the next quarter.
Worry ifOperating costs are above $415 million for the next quarter.
Why it matters: Good results could improve the pipeline. They would also support the company's growth plans.
Supportive ifResults from the RM-718 trial show significant BMI reduction in patients with acquired HO.
Worry ifResults from the RM-718 trial show no significant BMI reduction.
Why it matters: More market approval can lead to higher sales and growth for Rhythm Pharmaceuticals.
Supportive ifA press release confirms new market approvals for IMCIVREE in more regions.
Worry ifNo new market authorizations announced within the next six months.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$169 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $501 loss on $10,000 · 5.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,554 loss on $10,000 · 35.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Starting this trial would show progress for Rhythm. It shows they want to create new treatments.
Supportive ifRhythm says they will start the important Phase 3 trial for bivamelagon by the end of 2026.
Worry ifThere is no news about starting the Phase 3 trial for bivamelagon by the end of 2026.
Why it matters: A good decision would help Rhythm grow its market. This would increase their money-making chances.
Supportive ifJapan's PMDA grants approval for IMCIVREE for acquired HO.
Worry ifJapan's PMDA denies approval for IMCIVREE for acquired HO.
Why it matters: A strong revenue number would show that people still want IMCIVREE. This would support growth.
Supportive ifU.S. revenue from IMCIVREE exceeds $51 million in Q3 2026.
Worry ifU.S. revenue from IMCIVREE falls below $51 million in Q3 2026.
Why it matters: Good results would help Rhythm grow their pipeline. It would also support their clinical approach.
Supportive ifPhase 3 trial results for setmelanotide in PWS show big gains in BMI. They also show big gains in hyperphagia scores.
Worry ifPhase 3 trial results for setmelanotide in PWS show no big improvements.
Why it matters: Good results would help develop setmelanotide further. This would improve Rhythm's pipeline.
Watch forRhythm shares good six-month results from the Phase 2 trial of setmelanotide in PWS.
Also watch forRhythm shares bad news. The six-month results from the Phase 2 trial of setmelanotide in PWS are disappointing.
Why it matters: If healthcare sector revenue growth speeds up, it could help Rhythm's performance. This signals a better market environment.
Supportive ifHealthcare sector revenue growth rises back toward 10% or higher.
Worry ifHealthcare sector revenue growth remains below 10% or continues to slow.
Why it matters: Good results would show that RM-718 works well. This would make the pipeline more trusted.
Supportive ifPositive results from the Phase 1/2 trial of RM-718 are announced in Q3 2026.
Worry ifBad results or delays in reporting RM-718 trial results.